Prostate Cancer Reports


Volume 3 Number 12
December 2015

Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 12, December


CONTENTS



CASE REPORTS
CLASSIFICATION
DIAGNOSIS AND EVALUATION
EPIDEMIOLOGY AND RISK FACTORS
ETIOLOGY AND PATHOGENESIS
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOME
TREATMENT
RADICAL PROSTATECTOMY
DEFINITIVE RADIOTHERAPY
OPTIONS OTHER THAN SURGERY AND RADIOTHERAPY
HORMONAL THERAPY
METASTATIC PROSTATE CANCER
PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT
CLINICAL RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT
CASTRATION-RESISTANT  PROSTATE CANCER





CASE REPORTS



Ellent E, Matrana MR.
Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery.
Clin Genitourin Cancer. 2015 Nov 17. pii: S1558-7673(15)00306-7. doi: 10.1016/j.clgc.2015.11.007. [Epub ahead of print]
Source | Abstract | Similar articles




Mandaliya H, Sung J, Hill J, Samali R, George M.
Prostate Cancer: Cases of Rare Presentation and Rare Metastasis.
Case Rep Oncol. 2015 Nov 26;8(3):526-9. doi: 10.1159/000442045. eCollection 2015 Sep-Dec.
Source | Abstract | Full text | Similar articles

CLASSIFICATION



Gulavita P, Hakim SW, Schieda N, Breau RH, Morash C, Keefe DT, Robertson SJ, Mai KT, Belanger EC, Flood TA.
Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):302-6. doi: 10.5489/cuaj.2976.
Source | Abstract | Full text | Similar articles

DIAGNOSIS AND EVALUATION



Screening and early detection


Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D.
Prostate Cancer Early Detection, Version 2.2015.
J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61.
Source | Abstract | Full text | Similar articles




Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.
Screening for Familial and Hereditary Prostate Cancer.
Int J Cancer. 2015 Dec 5. doi: 10.1002/ijc.29949. [Epub ahead of print]
Source | Abstract | Similar articles




Shen X, Kumar P.
Trade-Off Between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
J Urol. 2015 Dec 2. pii: S0022-5347(15)05348-3. doi: 10.1016/j.juro.2015.11.056. [Epub ahead of print]
Source | Abstract | Similar articles




Clinical diagnosis


Prostate-specific antigen


Genomic markers


Glass AG, Leo MC, Haddad Z, Yousefi K, du Plessis M, Chen C, Choeurng V, Abdollah F, Robbins B, Ra S, Richert-Boe KE, Buerki C, Pearson K, Davicioni E, Weinmann S.
Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community-based healthcare setting.
J Urol. 2015 Nov 25. pii: S0022-5347(15)05315-X. doi: 10.1016/j.juro.2015.11.044. [Epub ahead of print]
Source | Abstract | Similar articles




Taneja SS.
Re: A Genomic Classifier Improves Prediction of Metastatic Disease within 5 Years after Surgery in Node-Negative High-Risk Prostate Cancer Patients Managed by Radical Prostatectomy without Adjuvant Therapy.
J Urol. 2016 Jan;195(1):95. doi: 10.1016/j.juro.2015.10.056. Epub 2015 Oct 23.
Source | Abstract | Full text | Similar articles




Role of imaging


Multiparametric MRI


Loffroy R, Chevallier O, Moulin M, Favelier S, Genson PY, Pottecher P, Crehange G, Cochet A, Cormier L.
Current role of multiparametric magnetic resonance imaging for prostate cancer.
Quant Imaging Med Surg. 2015 Oct;5(5):754-64. doi: 10.3978/j.issn.2223-4292.2015.10.08.
Source | Abstract | Full text | Similar articles




Hernandez D, Salas D, Giménez D, Buitrago P, Esquena S, Palou J, de la Torre P, Pernas J, Gich I, de Segura GG, Craven-Bartle J, Sancho G.
Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy.
Radiat Oncol. 2015 Dec 24;10(1):262. doi: 10.1186/s13014-015-0574-6.
Source | Abstract | Full text | Similar articles




Gleason score


Overview


Epstein JI.
Prostate Cancer Grading: A Contemporary Photomontage.
Am J Surg Pathol. 2016 Jan;40(1):137. doi: 10.1097/PAS.0000000000000563.
Source | Abstract | Full text | Similar articles




Epstein JI, Montironi R.
Grading of prostate cancer in the 21st century.
Urologia. 2015 Dec 14;0(0):0. doi: 10.5301/uro.5000163. [Epub ahead of print]
Source | Abstract | Similar articles




Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA.
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
Eur Urol. 2015 Jul 9. pii: S0302-2838(15)00557-6. doi: 10.1016/j.eururo.2015.06.046. [Epub ahead of print]
Source | Abstract | Similar articles




Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; and the Grading Committee.
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Am J Surg Pathol. 2015 Oct 21. [Epub ahead of print]
Source | Abstract | Similar articles




Kates M, Sopko NA, Han M, Partin AW, Epstein JI.
Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases.
J Urol. 2015 Aug 8. pii: S0022-5347(15)04530-9. doi: 10.1016/j.juro.2015.08.002. [Epub ahead of print]
Source | Abstract | Similar articles




Kench J.
The New ISUP Modified Gleason Grading System & ICCR Datasets for Prostate Cancer
ANZUP ASM 2015 (http://anzup.org.au)
Source (Slides) | Abstract | Full text




Kryvenko ON, Epstein JI.
Changes in prostate cancer grading: Including a new patient-centric grading system.
Prostate. 2015 Dec 28. doi: 10.1002/pros.23142. [Epub ahead of print]
Source | Abstract | Similar articles




Gleason score 6


Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT.
Gleason 6 Prostate Cancer: Translating Biology into Population Health.
J Urol. 2015 Sep;194(3):626-34. doi: 10.1016/j.juro.2015.01.126. Epub 2015 Apr 4.
Source | Abstract | Full text | Similar articles




Knüchel R.
Gleason Score 6 - Prostate Cancer or Benign Variant?
Oncol Res Treat. 2015;38(12):629-32. doi: 10.1159/000441735. Epub 2015 Nov 12.
Source | Abstract | Similar articles




Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM.
Should Gleason 6 be labeled as cancer?
Curr Opin Urol. 2015 May;25(3):238-45. doi: 10.1097/MOU.0000000000000165.
Source | Abstract | Similar articles




Loeb S, Montorsi F, Catto JW.
Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?
Eur Urol. 2015 Jul;68(1):1-2. doi: 10.1016/j.eururo.2015.02.038. Epub 2015 Mar 11.
Source | Abstract | Full text | Similar articles




Clinical staging


New imaging modalities


van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
BJU Int. 2015 Dec 18. doi: 10.1111/bju.13397. [Epub ahead of print]
Source | Abstract | Similar articles

EPIDEMIOLOGY AND RISK FACTORS



Prostate cancer incidence


Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT.
Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.
Cancer Med. 2015 Dec 2. doi: 10.1002/cam4.549. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hoffman RM, Meisner A, Arap W, Barry M, Shah S, Zeliadt S, Wiggins CL.
Trends in United States prostate cancer incidence rates by age and stage, 1995-2012.
Cancer Epidemiol Biomarkers Prev. 2015 Dec 8. pii: cebp.0723.2015. [Epub ahead of print]
Source | Abstract | Similar articles




Risk of second cancer


Risk of malignant melanoma


Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P.
Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.
Int J Cancer. 2015 Dec 14. doi: 10.1002/ijc.29961. [Epub ahead of print]
Source | Abstract | Similar articles




Dietary pattern


Niclis C, Román MD, Osella AR, Eynard AR, Díaz Mdel P.
Traditional Dietary Pattern Increases Risk of Prostate Cancer in Argentina: Results of a Multilevel Modeling and Bias Analysis from a Case-Control Study.
J Cancer Epidemiol. 2015;2015:179562. doi: 10.1155/2015/179562. Epub 2015 Nov 16.
Source | Abstract | Full text | Similar articles




Pesticides


Lewis-Mikhael AM, Bueno-Cavanillas A, Ofir Guiron T, Olmedo-Requena R, Delgado-Rodríguez M, Jiménez-Moleón JJ.
Occupational exposure to pesticides and prostate cancer: a systematic review and meta-analysis.
Occup Environ Med. 2015 Dec 7. pii: oemed-2014-102692. doi: 10.1136/oemed-2014-102692. [Epub ahead of print]
Source | Abstract | Similar articles




Red meat


Bylsma LC, Alexander DD.
A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer.
Nutr J. 2015 Dec 21;14(1):125. doi: 10.1186/s12937-015-0111-3.
Source | Abstract | Full text | Similar articles




Wu K, Spiegelman D, Hou T, Albanes D, Allen NE, Berndt SI, van den Brandt PA, Giles GG, Giovannucci E, Goldbohm RA, Goodman GG, Goodman PJ, Håkansson N, Inoue M, Key TJ, Kolonel LN, Männistö S, McCullough ML, Neuhouser ML, Park Y, Platz EA, Schenk JM, Sinha R, Stampfer MJ, Stevens VL, Tsugane S, Visvanathan K, Wilkens LR, Wolk A, Ziegler RG, Smith-Warner SA.
Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies.
Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29973. [Epub ahead of print]
Source | Abstract | Similar articles

ETIOLOGY AND PATHOGENESIS



Chemosensitivity


Das A, Durrant D, Mitchell C, Dent P, Batra SK, Kukreja RC.
Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95.
Oncotarget. 2015 Dec 24. doi: 10.18632/oncotarget.6749. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Metastasis


Anantharaman A, Friedlander TW.
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Urol Oncol. 2015 Dec 16. pii: S1078-1439(15)00555-4. doi: 10.1016/j.urolonc.2015.11.003. [Epub ahead of print]
Source | Abstract | Similar articles




Weidle UH, Birzele F, Kollmorgen G, Rüger R.
Molecular Mechanisms of Bone Metastasis.
Cancer Genomics Proteomics. 2016 01-02;13(1):1-12.
Source | Abstract | Full text | Similar articles




Prostatic intraepithelial neoplasia


Patel P, Nayak JG, Biljetina Z, Donnelly B, Trpkov K.
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy.
Can J Urol. 2015 Dec;22(6):8056-62.
Source | Abstract | Similar articles




Testosterone


Michaud JE, Billups KL, Partin AW.
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.
Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633.
Source | Abstract | Full text | Similar articles

INTEGRATIVE MEDICINE



Complementary and alternative medicine


PDQ Cancer Complementary and Alternative Medicine Editorial Board.
Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2015 Jun 25.
Source (Book) | Abstract | Full text | Similar articles




Nutrition, and dietary supplements


PDQ Cancer Complementary and Alternative Medicine Editorial Board.
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2015 Oct 21.
Source (Book) | Abstract | Full text




PDQ Cancer Complementary and Alternative Medicine Editorial Board.
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Patient Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2015 Dec 11.
Source (Book) | Abstract | Full text




Ramos-Torres Á, Bort A, Morell C, Rodríguez-Henche N, Díaz-Laviada I.
The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells.
Oncotarget. 2015 Nov 27. doi: 10.18632/oncotarget.6415. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Fish oil


Haas-Haseman M.
Weighing the Benefits of Fish Oil for Patients With Prostate Cancer: A Subcohort Review From the SELECT Trial.
J Adv Pract Oncol. 2015 Jul-Aug;6(4):376-8. Epub 2015 Jul 1.
Source | Abstract | Full text | Similar articles

OVERALL MANAGEMENT



Overviews


Heidenreich A.
New Developments in the Management of Prostate Cancer.
Oncol Res Treat. 2015;38(12):628. doi: 10.1159/000442269. Epub 2015 Nov 18.
Source | Abstract | Full text | Similar articles




Practical guides


Jaiswal S, Sarmad R, Arora S, Dasaraju R, Sarmad K.
Prostate Cancer for the Internist.
N Am J Med Sci. 2015 Oct;7(10):429-35. doi: 10.4103/1947-2714.168660.
Source | Abstract | Full text | Similar articles




PDQ Adult Treatment Editorial Board.
Prostate Cancer Treatment (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2015 Oct 23.
Source (Book) | Abstract | Full text




PDQ Adult Treatment Editorial Board.
Prostate Cancer Treatment (PDQ®): Patient Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. 2015 Jul 31.
Source (Book) | Abstract | Full text

PROGNOSIS AND OUTCOME



Prediction of cancer detection at repeat biopsy


Kim TS, Ko KJ, Shin SJ, Ryoo HS, Song W, Sung HH, Han DH, Jeong BC, Seo SI, Jeon SS, Lee KS, Lee SW, Lee HM, Choi HY, Jeon HG.
Multiple cores of high grade prostatic intraepithelial neoplasia and any core of atypia on first biopsy are significant predictor for cancer detection at a repeat biopsy.
Korean J Urol. 2015 Dec;56(12):796-802. doi: 10.4111/kju.2015.56.12.796. Epub 2015 Nov 26.
Source | Abstract | Full text | Similar articles




Prediction of positive lymph nodes at radical prostatectomy


Yiakoumos T, Kälble T, Rausch S.
Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy.
Urol Ann. 2015 Oct-Dec;7(4):433-7. doi: 10.4103/0974-7796.152118.
Source | Abstract | Full text | Similar articles




Prediction of metastatic cancer in patients initially managed with active surveillance


Yamamoto T, Musunuru B, Vesprini D, Zhang L, Ghanem G, Loblaw A, Klotz L.
Metastatic Prostate Cancer in Men Initially Managed with Active Surveillance.
J Urol. 2015 Dec 17. pii: S0022-5347(15)05445-2. doi: 10.1016/j.juro.2015.11.075. [Epub ahead of print]
Source | Abstract | Similar articles




Prediction of recurrence after prostatectomy and radiation therapy using the 2015 Gleason Grade Groups


Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.
Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.
Eur Urol. 2015 Dec 17. pii: S0302-2838(15)01207-5. doi: 10.1016/j.eururo.2015.11.036. [Epub ahead of print]
Source | Abstract | Similar articles




Prognostic effect of concomitant pharmaceutical treatment


Statins


Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ.
Statin use and risk of disease recurrence and death after radical prostatectomy.
Prostate. 2015 Dec 22. doi: 10.1002/pros.23138. [Epub ahead of print]
Source | Abstract | Similar articles




Prognostic value of PSA kinetics in untreated patients


Thomsen FB, Brasso K, Berg KD, Gerds TA, Johansson JE, Angelsen A, Tammela TL, Iversen P; Scandinavian Prostate Cancer Group.
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study.
Ann Oncol. 2015 Dec 17. pii: mdv607. [Epub ahead of print]
Source | Abstract | Similar articles




Prognostic value of PSA-response to salvage radiotherapy after radical prostatectomy


Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T.
The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
Radiother Oncol. 2015 Nov 30. pii: S0167-8140(15)00595-2. doi: 10.1016/j.radonc.2015.10.028. [Epub ahead of print]
Source | Abstract | Similar articles




Oncologic outcome of radical prostatectomy for localized prostate cancer


Laparoscopic and robot-assisted radical prostatectomy


Mortezavi A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, Hermanns T.
Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years.
Clin Genitourin Cancer. 2015 Nov 17. pii: S1558-7673(15)00305-5. doi: 10.1016/j.clgc.2015.11.006. [Epub ahead of print]
Source | Abstract | Similar articles




Survival outcomes in young patients treated with radical prostatectomy for high-risk prostate cancer


Dell׳Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Urol Oncol. 2015 Dec 16. pii: S1078-1439(15)00570-0. doi: 10.1016/j.urolonc.2015.11.018. [Epub ahead of print]
Source | Abstract | Similar articles




Survival and clinicopathologic outcomes following radical prostatectomy in patients with family history of prostate cancer


Westerman ME, Gershman B, Karnes RJ, Thompson RH, Rangel L, Boorjian SA.
Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy.
World J Urol. 2015 Dec 9. [Epub ahead of print]
Source | Abstract | Similar articles




Survival outcomes after prostate cancer treatment with surgery or radiotherapy for localized prostate cancer


Wallis CJ, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK.
Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol. 2015 Nov 30. pii: S0302-2838(15)01160-4. doi: 10.1016/j.eururo.2015.11.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer


Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.
Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Urol Oncol. 2015 Dec 11. pii: S1078-1439(15)00556-6. doi: 10.1016/j.urolonc.2015.11.004. [Epub ahead of print]
Source | Abstract | Similar articles




Survival outcomes at biochemical recurrence after radical prostatectomy


Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.
Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
Eur J Cancer. 2015 Dec 18;54:27-34. doi: 10.1016/j.ejca.2015.11.004. [Epub ahead of print]
Source | Abstract | Similar articles




Survival outcomes in patients with mCRPC treated with abiraterone after docetaxel


Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI.
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Ann Oncol. 2015 Dec 18. pii: mdv594. [Epub ahead of print]
Source | Abstract | Full text | Similar articles

TREATMENT



Decision making


de Carvalho TM, Heijnsdijk EA, de Koning HJ.
Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
Int J Cancer. 2015 Dec 22. doi: 10.1002/ijc.29976. [Epub ahead of print]
Source | Abstract | Similar articles




Feldman-Stewart D, Siemens DR.
What if?: Regret and cancer-related decisions.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):295-355. doi: 10.5489/cuaj.3372.
Source | Abstract | Full text | Similar articles




Qi R, Moul J.
High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy.
Oncol Res Treat. 2015;38(12):639-44. doi: 10.1159/000441736. Epub 2015 Nov 16.
Source | Abstract | Full text | Similar articles




Erectile function


Putora PM, Engeler D, Haile SR, Graf N, Buchauer K, Schmid HP, Plasswilm L.
Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
Strahlenther Onkol. 2015 Dec 28. [Epub ahead of print]
Source | Abstract | Similar articles




Comparison of orchiectomy and chemical castration


Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
JAMA Oncol. 2015 Dec 23:1-8. doi: 10.1001/jamaoncol.2015.4917. [Epub ahead of print]
Source | Abstract | Similar articles

RADICAL PROSTATECTOMY



Radical prostatectomy plus extended lymph node dissection in combination with immediate ADT


Yang Y, Luo Y, Hou GL, Huang QX, Pang J, Gao X.
Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up.
Clin Genitourin Cancer. 2015 Nov 18. pii: S1558-7673(15)00308-0. doi: 10.1016/j.clgc.2015.11.009. [Epub ahead of print]
Source | Abstract | Similar articles




Indication and extent of pelvic lymph node dissection (LND)


Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, Briganti A.
Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.
Urologia. 2015 Dec 16;0(0):0. doi: 10.5301/uro.5000139. [Epub ahead of print]
Source | Abstract | Similar articles




Comparative analysis of positive surgical margin rates in patients undergoing robot-assisted or retropubic radical prostatectomy


Veliev EL, Sokolov EA, Loran OB.
[Comparative analysis of positive surgical margin rates in patients undergoing robot- assisted or retropubic radical prostatectomy for prostate cancer].
Urologiia. 2015 Jul-Aug;(4):44-7.
Source | Abstract | Similar articles

DEFINITIVE RADIOTHERAPY



Low-dose rate (LDR) and high-dose rate (HDR) brachytherapy


LDR brachytherapy


Kumar AM, Smith KL, Reddy CA, Stephans KL, Klein EA, Ciezki JP.
Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy.
J Contemp Brachytherapy. 2015 Aug;7(4):241-6. doi: 10.5114/jcb.2015.54050. Epub 2015 Sep 14.
Source | Abstract | Full text | Similar articles




Stereotactic body radiotherapy


Vargo JA, Heron DE.
Editorial: Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate.
Front Oncol. 2015 Dec 7;5:266. doi: 10.3389/fonc.2015.00266. eCollection 2015.
Source | Abstract | Full text | Similar articles




Complications of radiotherapy


Hostova B, Matula P, Dubinsky P.
Prediction of toxicities of prostate cancer radiotherapy.
Neoplasma. 2015 Dec 7. doi: 10.4149/neo_2016_020. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lee YC, Hsieh CC, Li CY, Chuang JP, Lee JC.
Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer.
World J Surg. 2015 Dec 28. [Epub ahead of print]
Source | Abstract | Similar articles




Peach MS, Showalter TN, Ohri N.
Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.
Prostate Cancer. 2015;2015:624736. doi: 10.1155/2015/624736. Epub 2015 Nov 30.
Source | Abstract | Full text | Similar articles

OPTIONS OTHER THAN SURGERY AND RADIOTHERAPY



Focal therapy


Gandaglia G, Briganti A, Salonia A, Montorsi F.
Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?
Eur Urol. 2015 Nov 26. pii: S0302-2838(15)01164-1. doi: 10.1016/j.eururo.2015.11.014. [Epub ahead of print]
Source | Abstract | Similar articles




Yap T, Ahmed HU, Hindley RG, Guillaumier S, McCartan N, Dickinson L, Emberton M, Minhas S.
The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.
Eur Urol. 2015 Oct 30. pii: S0302-2838(15)01013-1. doi: 10.1016/j.eururo.2015.10.030. [Epub ahead of print]
Source | Abstract | Similar articles




Yap T, Ahmed HU, Hindley RG, Guillaumier S, McCartan N, Dickinson L, Emberton M, Minhas S.
Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.11.014: Focal Therapy Preserves Erectile Function in Men with Prostate Cancer.
Eur Urol. 2015 Dec 13. pii: S0302-2838(15)01208-7. doi: 10.1016/j.eururo.2015.11.037. [Epub ahead of print]
Source | Abstract | Similar articles

HORMONAL THERAPY



Androgen-deprivation therapy


Hussain M, Tangen C, Higano C, Vogelzang N, Thompson I.
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
J Clin Oncol. 2015 Nov 9. pii: JCO.2015.62.8065. [Epub ahead of print]
Source | Abstract | Similar articles




Park JC, Eisenberger MA.
Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
J Clin Oncol. 2015 Nov 30. pii: JCO641019. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Side effects of androgen-deprivation therapy


Risk of cardiovascular disease


Basaria S.
Cardiovascular disease associated with androgen-deprivation therapy: time to give it due respect.
J Clin Oncol. 2015 Apr 10;33(11):1232-4. doi: 10.1200/JCO.2014.60.2649. Epub 2015 Mar 9.
Source | Abstract | Full text | Similar articles




Bolla M, Créhange G.
Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy.
Nat Rev Urol. 2015 Dec 15. doi: 10.1038/nrurol.2015.295. [Epub ahead of print]
Source | Abstract | Similar articles




O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.
Source | Abstract | Similar articles




Zareba P, Duivenvoorden W, Leong DP, Pinthus JH.
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?
Therapeutic Advances in Urology Nov 30, 2015; doi: 10.1177/1756287215617872. Published online before print
Source | Abstract




Risk of ischemic stroke


Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF.
Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong.
Jpn J Clin Oncol. 2015 May;45(5):483-7. doi: 10.1093/jjco/hyv025. Epub 2015 Feb 26.
Source | Abstract | Full text | Similar articles




Risk of Alzheimer’s disease


Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, Shah NH.
Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
J Clin Oncol. 2015 Dec 7. pii: JCO636266. [Epub ahead of print]
Source | Abstract | Similar articles

METASTATIC PROSTATE CANCER



Chemotherapy and chemohormonal therapy


Gilson C, Sydes MR, Chowdhury S.
Will chemotherapy change the management of prostate cancer?
BJU Int. 2015 Dec 22. doi: 10.1111/bju.13400. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lam ET, Flaig TW.
Upfront Chemotherapy for Metastatic Prostate Cancer.
Oncology (Williston Park). 2015 Dec;29(12). pii: 214810.
Source | Abstract | Full text | Similar articles




Park JC, Eisenberger M.
Chemotherapy in Prostate Cancer Beyond Metastatic CRPC.
Oncology (Williston Park). 2015 Dec;29(12). pii: 214811.
Source | Abstract | Full text | Similar articles




Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
Source | Abstract | Similar articles




Taneja SS.
Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
J Urol. 2016 Jan;195(1):94-6. doi: 10.1016/j.juro.2015.10.055. Epub 2015 Oct 23.
Source | Abstract | Full text | Similar articles




Tannock I, Sternberg CN.
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy.
Ann Oncol. 2015 Dec 12. pii: mdv600. [Epub ahead of print]
Source | Abstract | Similar articles




van Soest RJ, de Wit R.
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
BMC Med. 2015 Dec 22;13(1):304. doi: 10.1186/s12916-015-0543-9.
Source | Abstract | Full text | Similar articles




Other treatment options


Valproic acid


Lee JE, Kim JH.
Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1.
Genet Mol Biol. 2015 Dec;38(4):527-33. doi: 10.1590/S1415-475738420150028.
Source | Abstract | Full text | Similar articles

PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT



Assessment of metastases


Acetate positron emission tomography (PET)


Spick C, Polanec SH, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas G.
Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
Anticancer Res. 2015 Dec;35(12):6787-91.
Source | Abstract | Similar articles




Treatment of PSA-only recurrences


Hormonal therapy


van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N.
Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178-1. doi: 10.1016/j.eururo.2015.11.023. [Epub ahead of print]
Source | Abstract | Similar articles




Treatment of PSA-only recurrence after radical prostatectomy


Salvage radiotherapy


Zimmermann M, Taussky D, Delouya G, Alenizi AM, Zorn KC.
Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E608-12. doi: 10.5489/cuaj.2815. Epub 2015 Sep 9.
Source | Abstract | Full text | Similar articles




Treatment of PSA-only recurrence after radiation therapy


Comparative analysis


Donnelly BJ.
Salvage therapies for prostate cancer: Keeping it in the mix.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):330. doi: 10.5489/cuaj.3374.
Source | Abstract | Full text | Similar articles




Siddiqui KM, Billia M, Williams A, Alzahrani A, Chin JL.
Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):325-9. doi: 10.5489/cuaj.3113.
Source | Abstract | Full text | Similar articles

CLINICAL RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT



Third-line therapy for clinical recurrence


Salvage therapy after radical prostatectomy and radiation tharapy


Rittberg R, Kroczak T, Fleshner N, Drachenberg D.
Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review.
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E671-2. doi: 10.5489/cuaj.2888. Epub 2015 Sep 9.
Source | Abstract | Full text | Similar articles




Treatment of metastasis as first site of recurrence after radical therapy


Craig J, Woulfe J, Sinclair J, Malone S.
Isolated brain metastases as first site of recurrence in prostate cancer: case report and review of the literature.
Curr Oncol. 2015 Dec;22(6):e493-7. doi: 10.3747/co.22.2542.
Source | Abstract | Full text | Similar articles

CASTRATION-RESISTANT  PROSTATE CANCER



Background, overview and outlook


Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M.
Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
Cancer Med. 2015 Dec 29. doi: 10.1002/cam4.576. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Park JC, Eisenberger MA.
Advances in the Treatment of Metastatic Prostate Cancer.
Mayo Clin Proc. 2015 Dec;90(12):1719-33. doi: 10.1016/j.mayocp.2015.10.010.
Source | Abstract | Full text | Similar articles




Salvage extended pelvic lymph node dissection


Osmonov DK, Aksenov AV, Jilg CA, Schultze-Seeman W, Naumann CM, Hamann MF, Bothe K, Jünemann KP.
[Salvage lymphadenectomy in patients with prostate cancer recurrence : A review].
Urologe A. 2015 Dec 19. [Epub ahead of print]
Source | Abstract | Similar articles




First-line treatment of mCRPC


Bedussi F, Valcamonico F, Mosca A, Sigala S, Ferrari L, Terrone C, Volta AD, Marchioro G, Ferrari V, Alabiso O, Memo M, Berruti A.
Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients.
Endocrine. 2015 Dec 21. [Epub ahead of print]
Source | Abstract | Similar articles




Kim W, Ryan CJ.
Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies.
J Comp Eff Res. 2016 Jan;5(1):5-7. doi: 10.2217/cer.15.61. Epub 2015 Dec 21.
Source | Abstract | Full text | Similar articles




Sipuleucel-T


Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
Can J Urol. 2015 Dec;22(6):8048-55.
Source | Abstract | Similar articles




Second-line treatment of mCRPC


Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Prostate. 2015 Dec 22. doi: 10.1002/pros.23141. [Epub ahead of print]
Source | Abstract | Similar articles